Dr. Koprivnikar is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
92 2nd St
Hackensack, NJ 07601Phone+1 551-996-3925Fax+1 551-996-0574
Education & Training
MedStar Health/Georgetown University HospitalFellowship, Hematology and Medical Oncology, 2009 - 2012- MedStar Health/Georgetown University HospitalResidency, Internal Medicine, 2006 - 2009
Sidney Kimmel Medical College at Thomas Jefferson UniversityClass of 2006
Certifications & Licensure
NJ State Medical License 2015 - 2025
DC State Medical License 2006 - 2016
MD State Medical License 2012 - 2016
VA State Medical License 2006 - 2014- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Single Agent and Combined Inhibition After Allogeneic Stem Cell Transplant Start of enrollment: 2019 Mar 08
- Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIs Start of enrollment: 2016 Nov 29
- Study of Crenolanib vs Midostaurin Following Induction Chemotherapy and Consolidation Therapy in Newly Diagnosed FLT3 Mutated AML Start of enrollment: 2018 Aug 15
- Join now to see all
Publications & Presentations
PubMed
- 3 citationsExpert consensus on the management of pharmacodynamic breakthrough-hemolysis in treated paroxysmal nocturnal hemoglobinuria.David Dingli, Carlos De Castro Iii, Jamie Koprivnikar, Austin Kulasekararaj, Jaroslaw Maciejewski
Hematology. 2024-12-01 - CPX-351 Pharmacokinetics and Safety in Adults with Hematologic Malignancies and Renal Function Impairment: Phase 1 Trial.Scott R Solomon, Bayard L Powell, Jamie Koprivnikar, Catherine Lai, Heather Male
Cancers. 2024-02-24 - Aspacytarabine for the treatment of patients with AML unfit for intensive chemotherapy: a phase 2 study.Jessica K Altman, Tsila Zuckerman, Jamie Koprivnikar, James McCloskey, Vamsi Kota
Blood Advances. 2023-12-26
Abstracts/Posters
- Blinatumomab in Combination with Tyrosine Kinase Inhibitors Safely and Effectively Induces Rapid, Deep, and Durable Molecular Responses in Relapsed and Refractory Phil...Jamie Koprivnikar, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Pharmacodynamic Responses to CC-90009, a Novel Cereblon E3 Ligase Modulator, in a Phase I Dose-Escalation Study in Relapsed or Refractory Acute Myeloid Leukemia (R/R AML)Jamie Koprivnikar, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Combined Venetoclax and Hypomethylating Agent (HMA) Therapy Induces High Response Rates in Patients with Myelodysplastic Syndrome Including Patients Previously Failing...Jamie Koprivnikar, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Lectures
- Molecular Epidemiologic Associations in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) within the United States2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Limitations to Receiving Allogeneic Hematopoietic Cell Transplantation for Treatment of Acute Myeloid Leukemia: A Large Multi-Center Prospective Longitudinal Observati...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Survival Differences Among Patients (pts) with Acute Myeloid Leukemia (AML) Treated with Allogeneic Hematopoietic Cell Transplantation (HCT) Versus Non-HCT Therapies: ...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Press Mentions
Alcohol Labels Should Carry Cancer Risk Warning, U.S. Surgeon General UrgesJanuary 3rd, 2025- U.S. Surgeon General Urges Alcohol Labels to Carry Cancer Risk WarningJanuary 3rd, 2025
- Why Dry January Could (And Should) Be Part of Effort to Prevent CancerJanuary 2nd, 2025
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
